FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

Rhea-AI Summary

The FDA has accepted REGENXBIO's (NASDAQ: RGNX) Biologics License Application for RGX-121, a pioneering gene therapy targeting Mucopolysaccharidosis II (MPS II). The application received Priority Review status with a PDUFA target date of November 9, 2025. This development follows a strategic partnership formed in January 2025 between REGENXBIO and Nippon Shinyaku, with NS Pharma (Nippon Shinyaku's subsidiary) set to handle U.S. commercialization upon approval. The partnership also includes RGX-111, a treatment for MPS I. If approved, RGX-121 would represent a first-in-class gene therapy option for MPS II patients.

Positive

• FDA granted Priority Review status, potentially expediting the approval process
• Strategic partnership with Nippon Shinyaku enhances commercialization capabilities
• First-in-class gene therapy potential indicates strong market positioning
• Clear commercialization pathway through NS Pharma in the U.S. market

Negative

• None.

News Market Reaction

+1.83%

1 alert

+1.83% News Effect

On the day this news was published, RGNX gained 1.83%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PARAMUS, N.J., May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) submission by REGENXBIO Inc. (REGENXBIO; Headquarters: Rockville, Maryland, USA; CEO: Curran M. Simpson, NASDAQ: RGNX) for RGX-121 (clemidsogene lanparvovec), a potential first-in-class, investigational gene therapy for the treatment of Mucopolysaccharidosis II (MPS II). The FDA granted REGENXBIO's BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of November 9, 2025.

In January 2025, Nippon Shinyaku and REGENXBIO entered into a strategic partnership for the development and commercialization of RGX-121, as well as RGX-111, which is for the treatment of MPS I. Upon potential approval of RGX-121, NS Pharma will be exclusively responsible for commercializing RGX-121 in the U.S.

"This FDA decision represents a significant milestone in bringing a new, potentially life-changing treatment option to patients in the MPS community," said NS Pharma President, Yukiteru Sugiyama, Ph.D. "We are excited about our partnership with REGENXBIO and the value of our combined expertise in generating renewed hope for MPS families."

For more details, please see the press release from REGENXBIO: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-fda-acceptance-and-priority-review-bla-rgx

About RGX-121 (clemidsogene lanparvovec)
RGX-121 is a potential one-time AAV therapeutic for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is structurally identical to normal I2S.

RGX-121 has received Orphan Drug Product, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA.

About MPS II
MPS II, or Hunter Syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme I2S leading to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the CNS. In severe forms of the disease, early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. Specific treatment to address the neurological manifestations of MPS II remains a significant unmet medical need. Key biomarkers of I2S enzymatic activity in MPS II patients include its substrate heparan sulfate (HS) D2S6, which has been shown to correlate with neurocognitive manifestations of the disorder.

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. For more information, please visit www.regenxbio.com.

About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. For more information, please visit nspharma.com.

US Media Contact:
media@nspharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-accepts-biologics-license-application-for-mucopolysaccharidosis-ii-treatment-302454515.html

SOURCE NS Pharma, Inc.

FAQ

When is the PDUFA date for REGENXBIO's (RGNX) RGX-121 gene therapy?

The FDA set a PDUFA target action date of November 9, 2025 for REGENXBIO's RGX-121 gene therapy for MPS II.

What is RGX-121 designed to treat?

RGX-121 is an investigational gene therapy designed to treat Mucopolysaccharidosis II (MPS II).

Who will commercialize REGENXBIO's RGX-121 in the United States?

NS Pharma, a subsidiary of Nippon Shinyaku, will be exclusively responsible for commercializing RGX-121 in the U.S. upon potential approval.

What type of FDA review did REGENXBIO's RGX-121 receive?

The FDA granted Priority Review status for REGENXBIO's Biologics License Application (BLA) for RGX-121.

When did REGENXBIO partner with Nippon Shinyaku for RGX-121?

REGENXBIO and Nippon Shinyaku entered into a strategic partnership in January 2025 for RGX-121 and RGX-111.